| Статус: | Unknown status |
| Фаза: | не указано |
| Начало: | 28 апреля 2020 г. |
| Окончание: | 1 сентября 2023 г. |
| Описание: | This study was designed to evaluate the efficacy and safety of Extimia® (INN - empegfilgrastim) in reducing the frequency, duration of neutropenia, the incidence of febrile neutropenia and infections caused by febrile neutropenia in patients with High and "Gray Zone" Risk Reccurrence Breast Cancer, Gastointestinal Cancers and Gynecological Malignancies |
| смотреть на ClinicalTrials.gov |